Zacks Investment Research
17 Jun 2026, 22:50 UTC · 2h ago
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Jun 2026, 22:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
CRISPR Therapeutics (CRSP) is projected to achieve a 733.26% year-over-year increase in quarterly revenue to $7.42 million. — Massive projected revenue growth typically signals a commercial inflection point or successful product launch, driving bullish sentiment.
+0.60Full-year revenue estimates for CRISPR Therapeutics are projected to grow by 722.82% to $28.88 million. — Strong annual growth expectations support a long-term bullish trajectory for the company's valuation.
+0.50The Zacks Consensus EPS estimate for CRISPR Therapeutics has increased by 4.26% over the past month. — Positive analyst revisions generally correlate with near-term stock price appreciation.
+0.30Continue reading
6 related stories
Search tags
The Medical - Biomedical and Genetics industry is ranked in the bottom 39% of all industries tracked by Zacks. — Weak industry-wide rankings suggest systemic headwinds for companies within this specific sector.
CRISPR Therapeutics currently holds a Zacks Rank of #3 (Hold). — A neutral rating suggests a lack of strong conviction from the model, resulting in minimal market movement.
+0.00Which stocks this story touches
The stock outperformed the market, showed strong monthly gains, and has significantly positive projected revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
